Growth Metrics

CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2016 - 2017)

Historic Non-Current Deferred Tax Liability for CytomX Therapeutics (CTMX) over the last 4 years, with Q3 2017 value amounting to $520000.0.

  • CytomX Therapeutics' Non-Current Deferred Tax Liability rose 136.45% to $520000.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $520000.0, marking a year-over-year increase of 136.45%. This contributed to the annual value of $513000.0 for FY2016, which is 118.34% up from last year.
  • As of Q3 2017, CytomX Therapeutics' Non-Current Deferred Tax Liability stood at $520000.0, which was up 136.45% from $539000.0 recorded in Q2 2017.
  • In the past 5 years, CytomX Therapeutics' Non-Current Deferred Tax Liability registered a high of $539000.0 during Q2 2017, and its lowest value of $499000.0 during Q4 2014.
  • Over the past 4 years, CytomX Therapeutics' median Non-Current Deferred Tax Liability value was $513000.0 (recorded in 2016), while the average stood at $513500.0.
  • The largest annual percentage gain for CytomX Therapeutics' Non-Current Deferred Tax Liability in the last 5 years was 506.82% (2017), contrasted with its biggest fall of 78.43% (2017).
  • CytomX Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $499000.0 in 2014, then grew by 1.6% to $507000.0 in 2015, then increased by 1.18% to $513000.0 in 2016, then grew by 1.36% to $520000.0 in 2017.
  • Its Non-Current Deferred Tax Liability stands at $520000.0 for Q3 2017, versus $539000.0 for Q2 2017 and $514000.0 for Q1 2017.